Background and purpose: The use of stereotactic ablative radiotherapy (SABR) for prostate cancer has increased significantly. However, SABR can elevate the risk of moderate gastrointestinal (GI) side effects. Rectal spacers mitigate this risk by reducing the rectal dose. This study evaluates the impact of rectal spacers in MR-guided adaptive radiotherapy (MRgART) for prostate SABR. Materials and methods: A retrospective analysis was conducted on twenty patients with localised prostate cancer treated on the Unity MR-Linac at a single centre. Half of the cohort (n = 10) had rectal spacers placed before treatment. The adapt-to-shape strategy was used for online MRgART, and non-adapted plans were later generated offline for comparison. Dosimetric assessments were made between spacer and no-spacer cohorts, and between online adapted and non-adapted plans. Clinician-reported outcomes for genitourinary (GU) and GI toxicity were assessed at 3-, 6-, and 12-months post-treatment using Common Terminology Criteria for Adverse Events v.5.0. Results: No grade 2 or higher toxicity was observed in either cohort. Overall, the dosimetric analysis showed comparable results between the cohorts for target volumes, with D95% of 36.3 Gy in the spacer cohort and 36.0 Gy in the no-spacer cohort (p = 0.08). The spacer cohort demonstrated significant benefits in all rectal dose objectives (p < 0.0001) and in some bladder objectives (V40, p = 0.03; V36, p = 0.03). Failure rates for achieving planning objectives were similar between spacer and no-spacer groups for online adapted plans, with most rates ranging from 0 % to 4 % in both groups. Conclusion: The findings from this cohort suggest that MRgART is safe and effective for prostate SABR, with comparable toxicity rates in both spacer and no-spacer cohorts. While rectal spacers offer dosimetric advantages, the adaptive nature of MRgART can mitigate some dosimetric disparities, potentially reducing the need for invasive spacer placement. However, further studies with larger patient populations are needed to confirm these results.

AbstractIntroductionOnline adaptive radiotherapy is well suited for stereotactic ablative radiotherapy (SABR) in pancreatic cancer due to considerable intrafractional tumour motion. This study aimed to assess intrafraction motion and generate adjusted planning target volume (PTV) margins required for online adaptive radiotherapy in pancreatic cancer treatment using abdominal compression on the magnetic resonance linear accelerator (MR‐Linac).MethodsMotion monitoring images obtained from 67 fractions for 15 previously treated pancreatic cancer patients were analysed. All patients received SABR (50 Gy in five fractions) on the MR‐Linac using abdominal compression. The analysis included quantification of intrafraction motion, leading to the development of adjusted PTV margins. The dosimetric impact of implementing the adjusted PTV was then evaluated in a cohort of 20 patients.ResultsIntrafraction motion indicated an average target displacement of 1–3 mm, resulting in an adjusted PTV margin of 2 mm in the right–left and superior–inferior directions, and 3 mm in the anterior–posterior direction. Plans incorporating these adjusted margins consistently demonstrated improved dose to target volumes, with improvements averaging 1.5 Gy in CTV D99%, 4.9 Gy in PTV D99% and 1.2 Gy in PTV‐high D90%, and better sparing of the organs at risk (OAR).ConclusionsThe improved target volume coverage and reduced OAR dose suggest potential for reducing current clinical margins for MR‐Linac treatment. However, it is important to note that decreasing margins may reduce safeguards against geographical misses. Nonetheless, the continued integration of gating systems on MR‐Linacs could provide confidence in adopting reduced margins.

Purpose T-1 mapping is a widely used quantitative MRI technique, but its tissue-specific values remain inconsistent across protocols, sites, and vendors. The ISMRM Reproducible Research and Quantitative MR study groups jointly launched a challenge to assess the reproducibility of a well-established inversion-recovery T-1 mapping technique, using acquisition details from a seminal T-1 mapping paper on a standardized phantom and in human brains. Methods The challenge used the acquisition protocol from Barral et al. (2010). Researchers collected T-1 mapping data on the ISMRM/NIST phantom and/or in human brains. Data submission, pipeline development, and analysis were conducted using open-source platforms. Intersubmission and intrasubmission comparisons were performed. Results Eighteen submissions (39 phantom and 56 human datasets) on scanners by three MRI vendors were collected at 3 T (except one, at 0.35 T). The mean coefficient of variation was 6.1% for intersubmission phantom measurements, and 2.9% for intrasubmission measurements. For humans, the intersubmission/intrasubmission coefficient of variation was 5.9/3.2% in the genu and 16/6.9% in the cortex. An interactive dashboard for data visualization was also eveloped: https://rrsg2020.dashboards.neurolibre.org. Conclusion The T-1 intersubmission variability was twice as high as the intrasubmission variability in both phantoms and human brains, indicating that the acquisition details in the original paper were insufficient to reproduce a quantitative MRI protocol. This study reports the inherent uncertainty in T-1 measures across independent research groups, bringing us one step closer to a practical clinical baseline of T-1 variations in vivo.

BACKGROUND AND PURPOSE:Magnetic resonance (MR)-guided radiotherapy (MRgRT) enhances treatment precision and adaptive capabilities, potentially supporting a simulation-free (sim-free) workflow. This work reports the first clinical implementation of a sim-free workflow using the MR-Linac for prostate cancer patients treated with stereotactic ablative radiotherapy (SABR). MATERIALS AND METHODS:Fifteen patients who had undergone a prostate-specific membrane antigen positron emission tomography/CT (PSMA-PET/CT) scan as part of diagnostic workup were included in this work. Two reference plans were generated per patient: one using PSMA-PET/CT (sim-free plan) and the other using standard simulation CT (simCT plan). Dosimetric evaluations included comparisons between simCT, sim-free, and first fraction plans. Timing measurements were conducted to assess durations for both simCT and sim-free pre-treatment workflows. RESULTS:All 15 patients underwent successful treatment using a sim-free workflow. Dosimetric differences between simCT, sim-free, and first fraction plans were minor and within acceptable clinical limits, with no major violations of standardised criteria. The sim-free workflow took on average 130 min, while the simCT workflow took 103 min. CONCLUSION:This work demonstrates the feasibility and benefits of sim-free MR-guided adaptive radiotherapy for prostate SABR, representing the first reported clinical experience in an ablative setting. By eliminating traditional simulation scans, this approach reduces patient burden by minimising hospital visits and enhances treatment accessibility.

Objective. This study aimed to investigate the dosimetric impact of using population-based relative electron density (RED) overrides in lieu of simulation computerized tomography (CT) in a magnetic resonance linear accelerator (MRL) workflow for male pelvis patients. Additionally, the feasibility of using prostate specific membrane antigen positron emission tomography/CT (PSMA-PET/CT) scans to assess patients' eligibility for this proposed workflow was examined.Approach. In this study, 74 male pelvis patients treated on an Elekta Unity 1.5 T MRL were retrospectively selected. The patients' individual RED values for 8 organs of interest were extracted from their simulation-CT images to establish population-based RED values. These values were used to generate individual (IndD) and population-based (PopD) RED dose plans, representing current and proposed MRL workflows, respectively. Lastly, this study compared RED values obtained from CT and PET-CT scanners in a phantom and a subset of patients.Results. Population-based RED values were mostly within two standard deviations of ICRU Report 46 values. PopD plans were comparable to IndD plans, with the average %difference magnitudes of 0.5%, 0.6%, and 0.6% for mean dose (all organs), D0.1cm3(non-target organs) and D95%/D98% (target organs), respectively. Both phantom and patient PET-CT derived RED values had high agreement with corresponding CT-derived values, with correlation coefficients ≥ 0.9.Significance. Population-based RED values were considered suitable in a simulation-free MRL treatment workflow. Utilizing these RED values resulted in similar dosimetric uncertainties as per the current workflow. Initial findings also suggested that PET-CT scans may be used to assess prospective patients' eligibility for the proposed workflow. Future investigations will evaluate the clinical feasibility of implementing this workflow for prospective patients in the clinical setting. This is aimed to reduce patient burden during radiotherapy and increase department efficiencies.

Objective.To provide an open-source software for repeatable and efficient quantification ofT1andT2relaxation times with the ISMRM/NIST system phantom. Quantitative magnetic resonance imaging (qMRI) biomarkers have the potential to improve disease detection, staging and monitoring of treatment response. Reference objects, such as the system phantom, play a major role in translating qMRI methods into the clinic. The currently available open-source software for ISMRM/NIST system phantom analysis, Phantom Viewer (PV), includes manual steps that are subject to variability.Approach.We developed the Magnetic Resonance BIomarker Assessment Software (MR-BIAS) to automatically extract system phantom relaxation times. The inter-observer variability (IOV) and time efficiency of MR-BIAS and PV was observed in six volunteers analysing three phantom datasets. The IOV was measured with the coefficient of variation (CV) of percent bias (%bias) inT1andT2with respect to NMR reference values. The accuracy of MR-BIAS was compared to a custom script from a published study of twelve phantom datasets. This included comparison of overall bias and %bias for variable inversion recovery (T1VIR), variable flip angle (T1VFA) and multiple spin-echo (T2MSE) relaxation models.Main results.MR-BIAS had a lower mean CV withT1VIR(0.03%) andT2MSE(0.05%) in comparison to PV withT1VIR(1.28%) andT2MSE(4.55%). The mean analysis duration was 9.7 times faster for MR-BIAS (0.8 min) than PV (7.6 min). There was no statistically significant difference in the overall bias, or the %bias for the majority of ROIs, as calculated by MR-BIAS or the custom script for all models.Significance.MR-BIAS has demonstrated repeatable and efficient analysis of the ISMRM/NIST system phantom, with comparable accuracy to previous studies. The software is freely available to the MRI community, providing a framework to automate required analysis tasks, with the flexibility to explore open questions and accelerate biomarker research.

This dataset includes both raw data and processed T1 maps obtained from the 2020 challenge on inversion recovery T1 mapping organized by the International Society in Magnetic Resonance in Medicine (ISMRM) Reproducible Research Study Group (RRSG). For a comprehensive overview of the data distribution submitted for this challenge, please visit https://rrsg2020.db.neurolibre.org. It's important to note that this dataset exclusively comprises ISMRM-NIST system phantom data. Dataset provided for NeuroLibre preprint. Author repo: https://github.com/rrsg2020/paper NeuroLibre fork:https://github.com/roboneurolibre/paper For details, please visit the corresponding NeuroLibre technical screening. https://neurolibre.org

We present the first case in the literature of a 78-year-old woman with recurrent cardiac sarcoma adjacent to a bioprosthetic mitral valve treated with magnetic resonance linear accelerator (MR-Linac) guided adaptive stereotactic ablative body radiotherapy (SABR). The patient was treated using a 1.5 T Unity MR-Linac system (Elekta AB, Stockholm, Sweden). The mean gross tumour volume (GTV) size was 17.9 cm(3) (range 16.6-18.9 cm(3)) based on daily contours and the mean dose received by the GTV was 41.4 Gy (range 40.9-41.6 Gy) in five fractions. All fractions were completed as planned and the patient tolerated the treatment well with no acute toxicity reported. Follow-up appointments at 2 and 5 months after the last treatment showed stable disease and good symptomatic relief. Results of transthoracic echocardiogram after radiotherapy showed that the mitral valve prosthesis was normally seated with regular functionality. This study provides evidence that MR-Linac guided adaptive SABR is a safe and viable option for the treatment of recurrent cardiac sarcoma with mitral valve bioprosthesis.

The magnetic resonance linear accelerator (MR-Linac) offers a new treatment paradigm, providing improved visualisation of targets and organs at risk while allowing for daily adaptation of treatment plans in real time. Online MR-guided adaptive treatment has reduced treatment uncertainties; however, the additional treatment time and resource requirements may be a concern. We present our experience of integrating an MR-Linac into a busy department and provide recommendations for improved clinical and resource efficiency. Furthermore, we discuss potential future technological innovations that can further optimise clinical productivity in a busy department.

AbstractPurposeTo assess the technical performance of the apparent diffusion coefficient (ADC) on a dedicated 3T radiotherapy scanner, using a standardized phantom and sequences. Investigations into factors that could impact the technical performance of ADC in the clinic were also completed, including changing the slice‐encoded imaging direction and the reference sample ADC value.MethodsADC acquisitions were performed monthly on an isotropic diffusion phantom over 1 year. Measurements of ADC %bias, coefficients of variation for short‐/long‐term repeatability and precision (CVST/CVLT and CVP), and b‐value dependency (Depb) were calculated. The measurements were then assessed according to the Quantitative Imaging Biomarker Alliance (QIBA) Diffusion Profile specifications.ResultsThe average of all measurements over the year was within Profile recommended ranges. This included when testing was performed in different imaging directions, and on samples that had different ADC reference values (0.4–1.1 μm2/ms). Results in the axial plane for the central water vial included a bias of +0.05%, CVST /CVLT/CVP = 0.1%/ 0.9%/0.4% and Depb = 0.4%.ConclusionsThe technical performance of ADC on a radiotherapy dedicated MRI scanner over the course of 12 months was considered conformant to the QIBA Profile. Quantifying these metrics and factors that may affect the performance is essential in progressing the use of ADC clinically: ensuring that the observed change of ADC in a tissue is due to a physiological response and not measurement variability.

AbstractPurposeTo determine baseline accuracy and reproducibility of T1 and T2 relaxation times over 12 months on a dedicated radiotherapy MRI scanner.MethodsAn International Society of Magnetic Resonance in Medicine/National Institute of Standards and Technology (ISMRM/NIST) System Phantom was scanned monthly on a 3T MRI scanner for 1 year. T1 was measured using inversion recovery (T1‐IR) and variable flip angle (T1‐VFA) sequences and T2 was measured using a multi‐echo spin echo (T2‐SE) sequence. For each vial in the phantom, accuracy errors (%bias) were determined by the relative differences in measured T1 and T2 times compared to reference values. Reproducibility was measured by the coefficient of variation (CV) of T1 and T2 measurements across monthly scans. Accuracy and reproducibility were mainly assessed on vials with relaxation times expected to be in physiological ranges at 3T.ResultsA strong linear correlation between measured and reference relaxation times was found for all sequences tested (R2 > 0.997). Baseline bias (and CV[%]) for T1‐IR, T1‐VFA and T2‐SE sequences were +2.0% (2.1), +6.5% (4.2), and +8.5% (1.9), respectively.ConclusionsThe accuracy and reproducibility of T1 and T2 on the scanner were considered sufficient for the sequences tested. No longitudinal trends of variation were deduced, suggesting less frequent measurements are required following the establishment of baselines.

The responses of two silicon on insulator (SOI) 3-D microdosimeters developed by the Centre for Medical Radiation Physics were investigated with a range of different low energy ions, with high linear energy transfer (LET). The two microdosimeters n-SOI and p-SOI were able to measure the LET of different ions including 7Li, 12C, 16O, and 48Ti with ranges below $350~\mu \text{m}$ in silicon. No plasma effects were seen in the SOI microdosimeters when irradiated with the high LET ions. A Monte Carlo simulation using Geant4 was compared to the experimental measurements, whereby some discrepancies were observed for heavier ions at lower energies. This discrepancy can be partly attributed to uncertainties in the thickness of the energy degraders and overlayers of the devices. The microdosimetric measurements of low energy 16O ions were obtained and compared to a therapeutic 16O ion beam. The radiation hardness of the two devices was studied using the ion beam induced charge collection technique. Both types of the microdosimeters when biased had no essential changes in charge collection efficiency in the sensitive volume after irradiation with low energy ions.

A collaborative reproducibility challenge was launched to explore if an imaging protocol independently-implemented at multiple centers can reliably measure T1 using inversion recovery in a standardized quantitative MRI phantom (ISMRM/NIST). A total of 19 submissions were accepted, totalling 41 phantom T1 mapping datasets. Errors relative to the temperature-corrected reference T1 values were under 10% for the range of values expected in the human brain in vivo. All submitted phantom data, code, pipelines, and scripts were shared on open platforms.